# Uveal Melanoma: Biology, Prognostication, and Emerging Therapies to Outsmart an Immune-Cold Melanoma

## TL;DR

This paper reviews uveal melanoma, a rare eye cancer that is hard to treat because it hides from the immune system, and discusses new therapies that may improve patient survival.

## Contribution

The paper provides an updated review of emerging therapies and biological insights for uveal melanoma, highlighting new treatment approaches beyond standard immunotherapies.

## Key findings

- Uveal melanoma has unique genetic features that make it resistant to standard immunotherapies.
- New treatments like tebentafusp and liver-targeted therapies are showing promise in improving patient outcomes.
- Advances in molecular classification and immune-based strategies are reshaping treatment approaches for uveal melanoma.

## Abstract

This paper summarizes available treatment for uveal melanoma, a rare, aggressive cancer that originates in the eye. While treatments like surgery or radiation can control the tumor within the eye, about half of patients experience the spread of cancer, usually to the liver. Researchers now understand that uveal melanoma has unique genetic changes that obscure it from the immune system, which is why standard immunotherapies have limited efficacy. Recently, more tailored treatments are emerging including the bispecific antibody tebentafusp, advanced cell-based therapies, liver-focused treatments, and targeted drugs based on specific tumor biology. These advances are slowly improving the survival for patients with uveal melanoma.

Uveal melanoma (UM) is a rare but highly aggressive malignancy arising from melanocytes of the uveal tract. Despite high local control rates for primary disease, half of patients ultimately develop metastatic disease with historically dismal outcomes. Unlike cutaneous melanoma, UM is characterized by a low tumor mutational burden, distinct driver mutations, and an immunosuppressive tumor microenvironment which together limit the efficacy of immune checkpoint inhibitors. Over the past decade, major advancements in molecular classification, prognostication, and therapeutic development have reshaped the clinical landscape for some patients with UM. This review synthesizes the current understanding of UM epidemiology, characteristics, prognostic biomarkers, immune biology, and contemporary management for both localized and metastatic disease. While survival gains remain modest, the rapid expansion of biologically informed and immune-based strategies offers cautious optimism for improving outcomes in this historically treatment-refractory disease.